Keros Therapeutics, Inc. - מכפיל EV/Sales KROS

לוגו של חברה ציבורית Keros Therapeutics, Inc. (KROS)

The EV/Revenue ratio reflects the current market valuation of Keros Therapeutics (KROS), where -511.04 represents the latest metric reading. Growth potential is based on patents promising high margins upon drug approval. Success depends on trials of therapies for blood and muscle pathologies. Processes are being optimized through the implementation of laboratory robotics and automated data collection.

Keros Therapeutics - יחס שווי פעילות להכנסות KROS (תקופה 23.11.2025 - 20.11.2026)

KROS (Keros Therapeutics Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- מידע על כספים ותזרימי מזומנים:
הערכת שווי פונדמנטלית של החברה:KROS, kerostx.com
מוצר סדרתי של Keros Therapeutics, Inc.

To minimize investment risks, it is necessary to determine the degree of overpayment for an asset. This metric is calculated as the ratio of enterprise value (market capitalization plus net debt) to annual revenue. An analysis of the EV/Sales ratio for Keros Therapeutics (KROS) allows for the identification of overbought or undervalued stock zones. This chart reflects market expectations regarding the commercialization of anemia treatments, which is critically important for Keros Therapeutics (KROS), as its valuation is based on the potential for hematopoietic recovery.